Compound Evidence File
#EC-2026-0486
SLU-PP-332
Filed under Oral Tablets. The bureau holds 116 laboratory returns for this compound from 40 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
40 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 8 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 27 Jan 2026 | 23 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 9.9 | 10.0 | 11 Jun 2026 | 2 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Mar 2026 | 18 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 10.0 | 9.9 | 10.0 | 6 Mar 2026 | 5 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 16 Feb 2026 | 14 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 9.9 | 10.0 | 6 Dec 2025 | 17 Aug 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 10.0 | 10.0 | 10.0 | 6 Nov 2025 | 28 May 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 10.0 | 10.0 | 10.0 | 19 Apr 2026 | 2 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 10.0 | 10.0 | 10.0 | 21 Jun 2026 | 6 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 10.0 | 10.0 | 10.0 | 3 May 2026 | 7 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 19 Nov 2025 | 4 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Feb 2026 | 7 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 12 Nov 2025 | 11 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 7 Feb 2026 | 12 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 9.9 | 9.9 | 9.9 | 20 Mar 2026 | 21 May 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 9.9 | 9.9 | 9.9 | 16 Dec 2025 | 2 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 9.9 | 9.9 | 10.0 | 18 May 2026 | 5 Aug 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 1 May 2026 | 6 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 6 Jan 2026 | 3 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 9.9 | 26 Dec 2025 | 11 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 9.9 | 7 Apr 2026 | 24 Jul 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 9.1 | 8.1 | 10.0 | 23 May 2026 | 23 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 8 | 9.0 | 6.6 | 10.0 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 8.4 | 7.8 | 9.1 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 5 | 8.3 | 7.0 | 9.5 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 2 | 8.3 | 7.6 | 9.0 | 24 May 2026 | 24 May 2026 |
| BeiBangAnCASE #VI-2026-0899 | X | 3 | 8.2 | 6.3 | 10.0 | 9 Jun 2025 | 21 May 2026 |
| Lux Synth AminosCASE #VI-2026-0700 | X | 1 | 8.2 | 8.2 | 8.2 | 17 Dec 2024 | 17 Dec 2024 |
| HazelCASE #VI-2026-0392 | X | 1 | 8.0 | 8.0 | 8.0 | 2 Jul 2025 | 2 Jul 2025 |
| UtherCASE #VI-2026-0902 | X | 3 | 7.5 | 6.7 | 8.0 | 11 Jun 2025 | 19 Jan 2026 |
| Xingtai Lesda TechnologyCASE #VI-2026-0381 | X | 1 | 6.8 | 6.8 | 6.8 | 21 May 2025 | 21 May 2025 |
| Wolverine PeptidesCASE #VI-2026-0262 | X | 1 | 6.1 | 6.1 | 6.1 | 11 Jun 2025 | 11 Jun 2025 |
| Hunan Ruiwang Technology CenterCASE #VI-2026-0027 | X | 1 | 6.0 | 6.0 | 6.0 | 16 Mar 2025 | 16 Mar 2025 |
| Xingruida XDRCASE #VI-2026-0898 | X | 3 | 5.8 | 3.6 | 7.0 | 24 Apr 2025 | 23 May 2026 |
| DeuschemCASE #VI-2026-0004 | X | 2 | 4.7 | 3.8 | 5.5 | 13 Jun 2025 | 25 May 2026 |
| Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 | E | 3 | 4.3 | 1.5 | 5.7 | 21 May 2025 | 25 May 2026 |
| Yabang PeptideCASE #VI-2026-0148 | X | 1 | 3.2 | 3.2 | 3.2 | 24 Apr 2025 | 24 Apr 2025 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | X | 1 | 3.2 | 3.2 | 3.2 | 8 Jul 2025 | 8 Jul 2025 |
Open any subject to view the batch-level evidence for SLU-PP-332 alone.